Edition:
United States

Laboratorios Farmaceuticos ROVI SA (ROVI.MC)

ROVI.MC on Madrid SE C.A.T.S.

17.15EUR
20 Apr 2018
Change (% chg)

€-0.15 (-0.87%)
Prev Close
€17.30
Open
€17.05
Day's High
€17.20
Day's Low
€17.05
Volume
1,045
Avg. Vol
5,622
52-wk High
€18.75
52-wk Low
€14.20

Chart for

About

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast... (more)

Overall

Beta: 0.51
Market Cap(Mil.): €860.00
Shares Outstanding(Mil.): 50.00
Dividend: 0.12
Yield (%): 1.06

Financials

  ROVI.MC Industry Sector
P/E (TTM): 49.18 31.01 33.60
EPS (TTM): 0.35 -- --
ROI: 7.90 13.60 13.19
ROE: 9.19 15.26 15.00

BRIEF-Rovi Sees 2018 Operating Revenue Growth At Mid-Single-Digit Rate

Feb 20 Laboratorios Farmaceuticos ROVI SA (ROVI) :

Feb 20 2018

BRIEF-ROVI FY Net Profit Down At 17.2 Mln Euros

Feb 20 LABORATORIOS FARMACEUTICOS ROVI SA (ROVI) :

Feb 20 2018

BRIEF-Rovi Gets 45 Million Euro Loan From European Investment Bank

* GETS 45 MILLION EURO LOAN FROM EUROPEAN INVESTMENT BANK Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 21 2017

BRIEF-Rovi 9-month operating revenue up 6 pct at 203.4 mln euros YoY

* RECURRENT NET PROFIT DECREASED BY 4 PERCENT TO 17.0 MILLION EUROS IN 9-MONTH

Nov 08 2017

BRIEF-Rovi announces update on risperidone project

* ANNOUNCES UPDATE ON A PHASE III STUDY FOR A LONG-ACTING INJECTABLE (LAI) TO TREAT SCHIZOPHRENIA CALLED DORIA(PREVIOUSLY RISPERIDONE ISM)

Oct 24 2017

Earnings vs. Estimates